An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer.
A study demonstrated that exercise may have the power to strengthen the immune system in patients with multiple myeloma.
After four years of follow-up, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) maintained a clinically meaningful overall survival benefit versus sunitinib in the phase III CLEAR (Study 307)/KEYNOTE-581 trial of first-line treatment in patients with advanced renal cell carcinoma.
A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are significant invasive disease-free survival benefits in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.
In the phase II PHERGain study, 95.4% of patients who followed a chemotherapy de-escalation strategy using PHERGain’s adaptive design remained cancer-free after three years of follow-up, and around 30% of patients responded to a fully chemotherapy-free regimen as part of their treatment for HER2- positive breast cancer.
An interim analysis of the ongoing DESTINY-PanTumor02 phase II trial showed that Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful and durable responses across a broad range of HER2 expressing advanced solid tumors in previously treated patients.
In the largest sequencing study to date on testicular cancer, researchers at Children’s National Hospital have identified genes that contribute to testicular germ cell tumors (TGCT), the most common cancer among young, white men.
After four years of follow-up, final pre-specified overall survival analysis from the pivotal phase III CLEAR/KEYNOTE-581 trial showed that Keytruda plus Lenvima maintained a clinically meaningful OS benefit versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma, reducing the risk of death by 21%.
Preliminary results from eight patients in the phase I portion of the Acclaim-1 clinical study evaluating Reqorsa immunogene therapy (quaratusugene ozeplasmid) with Tagrisso (osimertinib) in patients with advanced, EGFR mutant non-small cell lung cancer whose disease progressed after Tagrisso showed that Reqorsa was generally well tolerated, as there were no dose limiting toxicities. Promising efficacy results were also observed.
A study by Fox Chase Cancer Center researchers found that as many as 23% of cystic renal masses may carry high grade, or aggressive, disease.
